| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:25535829 | IVR | 100 mg/L | 100 mg/L | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations |
| IVR | 100 mg/L | 100 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Causes insulin resistance | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Affects insulin signaling | Metabolic endocrine-mediated perturbations | |
| PMID:31260803 | IVR | 100 mg/kg | 100 mg/kg | Beta cell dysfunction | Metabolic endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Affects gluconeogenesis | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Reduced glucose levels | Metabolic endocrine-mediated perturbations | |
| PMID:39151622 | IVTH | 0.75 - 5 mg/L | 0.75 - 5 mg/L | Affects placental development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVTH | 1 mg/L | 1 mg/L | Oxidative stress in uterine cells | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Decreased placental weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.75 - 1 mg/L | 0.75 - 1 mg/L | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/L | 1 - 5 mg/L | Causes inflammation | Immunological endocrine-mediated perturbations | |
| IVTH | 0.75 - 1 mg/L | 0.75 - 1 mg/L | Induce apoptosis of placental cells | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.5 - 1 mg/L | 0.5 - 1 mg/L | Induce apoptosis of endometrial cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.75 - 5 mg/L | 0.75 - 5 mg/L | Affects placental development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.5 - 1 mg/L | 0.5 - 1 mg/L | Affects calcium transport | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.75 - 1 mg/L | 0.75 - 1 mg/L | Altered cell cycle in placental cells | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.5 - 1 mg/L | 0.5 - 1 mg/L | Altered cell cycle of endometrial cells | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.